
ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

BG Medicine wants to fill big gaps in diagnostic medicine. The biosciences researcher primarily provides drug research and development services to such top global pharmaceutical makers as Pfizer and AstraZeneca, US government agencies, and to the health care product divisions of companies like Mitsubishi. BG Medicine specializes in developing biomarkers, substances used to detect disease at a molecular level, that enable research into the causes of disease and the effectiveness of drugs used to treat them. Products in the planning and discovery stages include molecular diagnostic tests for heart disease, neurological disorders, and cancer.

Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

BioGenex Laboratories, Inc. company was founded in 1981 and is based in San Ramon, California. BioGenex Laboratories Inc provides automated systems that streamline operations in molecular and cellular pathology laboratories. It offers Xmatrx Dx, an automated staining system that includes detection kits, primary antibodies, probes, reagents, and consumables for immunohistochemistry (IHC), in situ hybridization (ISH) and special stains (SS); i6000 that is an automated staining system designed for clinical diagnostics and research laboratories; EZ-Retriever System v.2, a microwave-based time and temperature controlled system designed to unmask the antigens on the formalin-fixed paraffin-embedded (FFPE) tissue sections; i500 Integrated Labeling System, a portable barcode solution, which creates barcode and text labeling for histology and cytology slides; and Xmatrx Rx, a biomarker assay development and analysis system that offers possibilities for translational and clinical research. The company also provides antibodies, antigen retrieval, ancillary reagents, detection systems, special stains, and tissue controls. In addition, it provides DNA/RNA synthesis labeling reagents, phosphoramidite, and branching phosphoramidites. The company serves reference laboratories, hospital laboratories, cancer treatment centers, university medical centers, group practices, and drug discovery laboratories in pharmaceutical and biotechnology firms, as well as oligonucleotide houses and academic institutions. BioGenex Laboratories Inc markets its products through distributors in Africa, Asia, Australia, Europe, the Middle East, North America, and South America.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Par Pharmaceutical Companies, Inc. was founded in 1978 and is based in Woodcliff Lake, New Jersey. Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States. Its principal generic products include Metoprolol succinate ER, Fluticasone, Meclizine Hydrochloride, Cabergoline, Sumatriptan succinate injection, Propranolol HCl ER, amoxicillin products, Dronabinol, Ibuprofen Rx, Megestrol oral suspension, Methimazole, Fluoxetine, Lovastatin, Tramadol HCl and acetaminophen tablets, Ranitidine HCl Syrup, Quinapril, and Cefprozil. The company offers its drugs in the solid oral dosage form, such as tablets, caplets, and two-piece hard-shell capsules, as well as oral suspension products and certain products in the semi-solid form of a cream.It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, clinics, and government agencies. The company's brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; and NanoCrystal Dispersion for megestrol acetate oral suspension. It has a joint venture with Rhodes Technology to research, develop, commercialize, and market pharmaceutical preparations for human therapy; a license and commercialization agreement with Intellipharmaceutics Corp. for the development of Dexmethylphenidate XR; and a development and supply agreement with Cipla Limited for the development of one generic product. The company has a collaboration agreement with Actavis Group for the development of 4 extended release generic products, such as Nifedipine XR, Methylphenidate LA, Zolpidem CR, and Alfuzosin.

Cell Therapeutics, Inc. company was founded in 1991 and is headquartered in Seattle, Washington. Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)





